These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30614439)

  • 21. Iron (III) isomaltoside 1000.
    Mace TA; Syed A; Bhandari S
    Expert Rev Hematol; 2013 Jun; 6(3):239-46. PubMed ID: 23782077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer
    Mulder MB; van den Hoek HL; Birnie E; van Tilburg AJP; Westerman EM
    Br J Clin Pharmacol; 2019 Feb; 85(2):385-392. PubMed ID: 30393904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study.
    Covic A; Mircescu G
    Nephrol Dial Transplant; 2010 Aug; 25(8):2722-30. PubMed ID: 20190247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
    Pollock RF; Muduma G
    Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease.
    Reinisch W; Altorjay I; Zsigmond F; Primas C; Vogelsang H; Novacek G; Reinisch S; Thomsen LL
    Scand J Gastroenterol; 2015; 50(10):1226-33. PubMed ID: 25900645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ferric Maltol: A New Oral Iron Formulation for the Treatment of Iron Deficiency in Adults.
    Khoury A; Pagan KA; Farland MZ
    Ann Pharmacother; 2021 Feb; 55(2):222-229. PubMed ID: 32633548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
    Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment.
    Pollock RF; Muduma G
    Expert Rev Hematol; 2019 Feb; 12(2):129-136. PubMed ID: 30689458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Assessment of iron deficiency anemia management in the general hospital of Grenoble: A 12-month follow-up of an intravenous ferric carboxymaltose treatment program in a cohort of patients with non-dialysis-dependent chronic kidney disease].
    Romanet T; Bedouch P; Zaoui P
    Nephrol Ther; 2019 Apr; 15(2):104-109. PubMed ID: 30803900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial
.
    Macdougall IC; Strauss WE; Dahl NV; Bernard K; Li Z
    Clin Nephrol; 2019 Apr; 91(4):237-245. PubMed ID: 30802204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ferric Citrate Dosing in Iron Deficiency Anemia in Nondialysis-Dependent Chronic Kidney Disease.
    Pergola PE; Belo D; Crawford P; Moustafa M; Luo W; Goldfarb-Rumyantzev A; Farag YMK
    Am J Nephrol; 2021; 52(7):572-581. PubMed ID: 34293738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous iron isomaltoside 1000 (Monofer®) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial).
    Johansson PI; Rasmussen AS; Thomsen LL
    Vox Sang; 2015 Oct; 109(3):257-66. PubMed ID: 25900643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France.
    Toledano A; Luporsi E; Morere JF; Scotté F; Laribi K; Barrière J; Huot-Marchand P; Duvillié L; Concas VH; Bugat R
    Support Care Cancer; 2016 Jan; 24(1):67-75. PubMed ID: 25921449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
    Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Nolen JG; Roger SD;
    Nephrol Dial Transplant; 2014 Nov; 29(11):2075-84. PubMed ID: 24891437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of intravenous iron supplementation in chronic kidney disease: an update.
    Macdougall IC; Geisser P
    Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous Iron Isomaltoside 1000 Reduces Postoperative Anemia in Patients Undergoing Elective Urologic Surgery and Those with Urosepsis.
    Goh HJ; Lee KS; Kim TH; Kim KN; Lim HJ; Kim KS; Yang WJ; Jo JK
    Drug Des Devel Ther; 2020; 14():5679-5687. PubMed ID: 33380788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale.
    Macdougall IC; Bock A; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Cushway T; Roger SD;
    Nephrol Dial Transplant; 2014 Apr; 29(4):843-50. PubMed ID: 24170814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment with Noripurum EV
    Venturieri MO; Komati JTS; Lopes LHC; Sdepanian VL
    Scand J Gastroenterol; 2019 Feb; 54(2):198-204. PubMed ID: 30782036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on intravenous iron choices.
    Larson DS; Coyne DW
    Curr Opin Nephrol Hypertens; 2014 Mar; 23(2):186-91. PubMed ID: 24401789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.